Launch of IDS-iSYS 17-OH Progesterone assay

Immunodiagnostic Systems Holdings plc.

Launch of IDS-iSYS 17-OH Progesterone assay - 1st assay in the new IDS fertility portfolio

Immunodiagnostic Systems Holdings plc (IDS), a specialty solution provider to the clinical laboratory diagnostic market, has launched the IDS-iSYS 17-OH Progesterone assay in the European market - a fully automated assay for use with the IDS-iSYS Automated System.

The launch of the IDS-iSYS 17-OH Progesterone assay is the first product released as part of the upcoming fertility (steroid hormones) portfolio.

The IDS-iSYS 17-OH Progesterone assay measures a patient's 17-OH Progesterone level and offers clinicians an easy, non-invasive way to diagnose disorders of the adrenal gland or the ovaries, such as Congenital Adrenal Hyperplasia (CAH) or Polycystic Ovarian Syndrome (PCOS). Women with PCOS will have higher than normal levels of 17-OH Progesterone which can be a cause of infertility.

As the only fully automated solution on the market, the IDS-iSYS 17-OH Progesterone assay allows laboratories to benefit from reduced time to first result for measurement of patient samples.

The Global market size of 17-OH Progesterone testing is estimated to be approximately£7-10 million.

For further information:

Immunodiagnostic Systems Holdings plc Tel: +44 (0) 191 519 0660

Partricio Lacalle, Chief Executive Officer

Paul Martin, Group Finance Director

Peel Hunt LLP Tel: +44 (0) 20 7418 8900

James Steel

Oliver Jackson